Associated Papers
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A et al.
Blood Advances, 2023
36287227 (PubMed )
Supplement: BLOODA_ADV-2022-008447-mmc1.xlsx › Table_S1
Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
Öztürk S et al.
Leukemia, 2022
34417556 (PubMed )
Supplement: 41375_2021_1381_MOESM10_ESM.xlsx › Supplementary_Table_5b
Select a paper to view details